* ADC Therapeutics press release [https://seekingalpha.com/pr/20300217-adc-therapeutics-reports-third-quarter-2025-financial-results-and-provides-operational-update] (ADCT [https://seekingalpha.com/symbol/ADCT]): Q3 Non-GAAP EPS of -$0.19.
* Revenue of $15.8M (-14.4% Y/Y) misses by $0.99M.
* Cash and cash equivalents: As of September 30, 2025, cash and cash equivalents were $234.7 million, compared to $250.9 million as of December 31, 2024.
MORE ON ADC THERAPEUTICS
* ADC Therapeutics SA 2025 Q2 - Results - Earnings Call Presentation [https://seekingalpha.com/article/4812645-adc-therapeutics-sa-2025-q2-results-earnings-call-presentation]
* ADC Therapeutics SA (ADCT) Q2 2025 Earnings Call Transcript [https://seekingalpha.com/article/4812644-adc-therapeutics-sa-adct-q2-2025-earnings-call-transcript]
* ADC Therapeutics Q3 Earnings Preview [https://seekingalpha.com/news/4518777-adc-therapeutics-q3-earnings-preview]
* ADC Therapeutics rises on $60M PIPE financing [https://seekingalpha.com/news/4503559-adc-therapeutics-rises-on-60m-pipe-financing]
* Seeking Alpha’s Quant Rating on ADC Therapeutics [https://seekingalpha.com/symbol/ADCT/ratings/quant-ratings]
ADC Therapeutics Non-GAAP EPS of -$0.19, revenue of $15.8M misses by $0.99M
Published 16 hours ago
Nov 10, 2025 at 12:36 PM
Positive
Auto